nimotuzumab
biocon,daiichi sankyo,oncoscience
['improve', 'nimotuzumab', 'pancreatic']
in the phase 3 #notable trial, the addition of nimotuzumab to gemcitabine lead to an improvement in overall survival compared with gemcitabine alone in patients with #kras wild-type advanced #pancreaticcancer, according to results presented #asco22 
Oncology news and insights from leading researchers and cancer centers.